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Abstract
Therapeutics based on transcription factors have the potential to revolutionize medicine but have 
had limited clinical success due to delivery problems1–4. The delivery of transcription factors is 
challenging because it requires developing a delivery vehicle that can complex transcription 
factors, target cells, and stimulate endosomal disruption, with minimal toxicity5,6. In this report we 
present a novel multifunctional oligonucleotide, termed DARTs (DNA Assembled Recombinant 
Transcription factors), which can deliver transcription factors with high efficiency in vivo. DARTs 
are composed of an oligonucleotide that contains a transcription factor binding sequence and 
hydrophobic membrane disruptive chains that are masked by acid cleavable galactose residues. 
DARTs have a unique molecular architecture, which allows them to bind transcription factors, 
trigger endocytosis in hepatocytes, and stimulate endosomal disruption. The DARTs target 
hepatocytes as a result of the galactose residues and can disrupt endosomes efficiently with 
minimal toxicity, because unmasking of their hydrophobic domains selectively occurs in the acidic 
environment of the endosome. We show here that DARTs can deliver the transcription factor 
Nuclear erythroid 2-related factor 2 (Nrf2) to the liver, catalyze the transcription of Nrf2 
downstream genes, and rescue mice from acetaminophen induced liver injury.
The delivery of transcription factors is a central challenge in medicine. Transcription factors 
control every major physiological process within a cell, ranging from cell fate determination 
to inflammation resolution2,3,7, and have the ability to correct the fundamental causes of a 
wide range of diseases. For example, the transcription factor Nrf2 transcribes genes that 
resolve states of chronic oxidative stress and inflammation, and can protect against 
numerous incurable inflammatory diseases, such as atherosclerosis, Alzheimer’s, and drug 
induced liver failure4,8,9. Therapeutics based on transcription factors, such as Nrf2, have 
tremendous therapeutic potential, but have been challenging to develop as therapeutics 
because of delivery problems4,10,11, and there is a great need for new transcription factor 
delivery vehicles9,12.
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In this report we present a transcription factor delivery vehicle, termed DARTs, which can 
deliver Nrf2 to the liver and rescue mice from acute liver failure. The chemical structure of 
the DARTs and the mechanism by which they are designed to deliver transcription factors 
are shown in Figure 1. DARTs are composed of an oligonucleotide that contains an Nrf2 
binding sequence and hydrophobic C32 alkyl chains that are “masked” by acid cleavable 
galactose residues, which are conjugated via acetal linkages13. The DARTs are able to 
complex Nrf2 because they contain an Nrf2 promoter sequence, which binds Nrf2 with high 
affinity, and can also target hepatocytes because they have galactose conjugated to their 3′ 
ends. In addition, the unique molecular architecture of the DARTs allows them to be pH 
sensitive membrane disruptive agents, and disrupt endosomes efficiently with minimal 
toxicity. The DARTs are designed to have minimal toxicity while they are circulating in the 
blood, because at pH 7.4, their hydrophobic domains are unable to interact with cell 
membranes due to the adjacent galactose groups. However, after endocytosis, the galactose 
groups of the DARTs are cleaved as a result of hydrolysis, and this activates the 
hydrophobic domains and allows them to disrupt the endosomal membrane.
The DARTs are designed to address several key challenges associated with delivering 
transcription factors in vivo. For example, transcription factors can be delivered via the 
DARTs by simply mixing them together. In contrast traditional protein delivery strategies 
require chemical modification of the protein or exposure to organic solvents, both of which 
frequently cause protein denaturation or the generation of antigenicity14. DARTs are well-
defined molecules that can also be synthesized on a large scale, and avoid the 
characterization and manufacturing problems associated with self-assembled systems. In 
addition, DARTs are able to disrupt endosomes without using cationic peptides or polymers 
and thus overcome the toxicity problems associated with traditional endosomal disruptive 
strategies15. Finally, the DART delivery strategy is modular, and a variety of transcription 
factors can potentially be delivered via the DART strategy by simply changing their 
oligonucleotide sequence and targeting moieties.
The pH sensitive hydrolysis of the acetal linkage in the DARTs is a critical feature of their 
molecular design. The DARTs need to be stable at pH 7.4 to allow for circulation in the 
blood with low toxicity, but hydrolyze rapidly at pH 5.0 and trigger endosomal disruption, 
before extensive degradation in the lysosome occurs. The hydrolysis kinetics of the DARTs 
was measured at pH 5.0 and pH 7.4, via gel electrophoresis (see Supplementary Information 
S3 for details). Figure 2a demonstrates that DARTs undergo pH sensitive hydrolysis with an 
estimated half-life of 41 minutes at pH 5.0, but have an estimated half-life of 12 hours at pH 
7.4. Intravenously injected galactose containing molecules are internalized by the liver 
within 1 hour16, and the pH 7.4 hydrolysis kinetics of the DARTs should be suitable for 
delivering transcription factors to the liver. In addition, the rapid hydrolysis of the DARTs at 
pH 5.0, suggests that they will trigger endosomal escape before extensive degradation of 
Nrf2 in the lysosomes occurs.
The acid catalyzed hydrolysis of the DARTs is designed to trigger endosomal disruption via 
unmasking of their hydrophobic domains. We therefore investigated if DARTs could disrupt 
liposomes in a pH sensitive manner using a calcein leakage assay (see Supplementary 
Information S4 for details). DARTs were incubated with calcein containing liposomes at 
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either pH 5.0 or 7.4 for 30 minutes, at concentrations between 10 – 30 μg/mL, and the 
disruption of liposomes was measured via the increase in calcein fluorescence. Figure 2b 
demonstrates that DARTs have pH sensitive membrane disruptive properties, and can 
disrupt lipid bilayers in an efficient manner. For example, calcein containing liposomes 
incubated with DARTs at a 20 μg/mL (1 μM) concentration at pH 5.0 released 
approximately 40% of their encapsulated calcein in 30 minutes, whereas liposomes 
incubated at pH 7.4 released only 10% of their encapsulated calcein. DARTs have a 
membrane disruptive capacity similar to commonly used endosomal disruptive polymers, 
such as co-polymers of diethylaminoethyl methacrylate and butyl methacrylate, which also 
require μg/mL concentrations to disrupt membranes, and this suggests that the DARTs will 
be able to enhance the cytoplasmic delivery of transcription factors17.
The DARTs are designed to complex Nrf2 because they contain the antioxidant responsive 
element (ARE) sequence, which is a DNA sequence found in the promoter region of Nrf2 
dependent genes. We performed experiments to determine if the DARTs could complex 
Nrf2. The binding of the DARTs with Nrf2 was determined via a competitive ELISA 
between DARTs and ARE DNA for binding to Nrf2. The results of this experiment are 
shown in the supporting information Figure S5 (see Supplementary Information S6 for 
details), and demonstrate that the DARTs bind Nrf2 with an affinity similar to unmodified 
ARE DNA. In addition, we performed experiments to determine if the DARTs could bind 
Nrf2 in serum. Alexa555-Nrf2 was complexed with the DARTs in 10% serum, and binding 
to the DARTs was analyzed by gel electrophoresis (see Supplementary Information S8 for 
details). Figure 2c demonstrates that Nrf2 can complex the DARTs in 10% serum, addition 
of Nrf2 to DARTs generated a high molecular weight band that was significantly larger than 
the free DARTs.
We performed fluorescent microscopy experiments to determine if DARTs could enhance 
the endosomal release of Nrf2. HepG2 cells were treated with DART-Alexa555-Nrf2 
complexes and the intracellular localization of Nrf2 was investigated via confocal 
microscopy, using Lysotracker green to mark endosomes and lysosomes (see Supplementary 
Information S9.1 for details). Figure 2d demonstrates that DARTs can dramatically alter the 
intracellular distribution of Nrf2, and causes a significant fraction of the delivered Nrf2 to 
localize in compartments distinct from lysosomes. In contrast, free Nrf2 is mostly found on 
the cell membrane or in lysosomes.
DARTs contain a tetravalent galactose group for hepatocyte targeting. We performed 
experiments to determine if the DARTs were efficiently internalized by hepatocytes. 
DARTs containing Cy3 were incubated with Hepa-1C1C7 and their uptake was compared 
against Cy3-labeled DNA via flow cytometry (see Supplementary Information S9 for 
details). Figure 3a demonstrates that the DARTs dramatically enhance the uptake of DNA, 
causing an 8 fold increase in mean red fluorescence versus free DNA. Based on these results 
we further performed in vivo biodistribution and pharmacokinetic experiments with Nrf2 
complexed with DARTs, to determine if the DARTs could enhance the accumulation of 
Nrf2 in the liver (see Supplementary Information S11.1 for details). Figure 3b demonstrates 
that the DARTs can increase the delivery of Nrf2 to the liver, causing an approximately 1.4 
fold increase in liver delivery compared to free Nrf2, suggesting that the galactose targeting 
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via the DARTs increases the delivery of Nrf2 to the liver. An increase in serum half-life was 
also observed with DART-Nrf2, which had a 1.3 fold increase in serum half-life over free 
Nrf2 (104 mins versus 83 mins) (see Supplementary Information S11.2 for details). The 1.3 
fold increase in serum half-life is consistent with the modest increase in molecular weight of 
Nrf2 caused by complexation with the DARTs. The molecular weight of the DART is 
approximately 20 kD and the DART-Nrf2 complex should therefore have a molecular 
weight that is only 35 % greater than free Nrf2. In addition, no evidence of systemic toxicity 
was observed in mice injected with Nrf2 complexed with the DARTs, as determined by 
blood TNF-α levels (Fig. S9).
DARTs are designed to deliver Nrf2 to hepatocytes, induce the expression of antioxidant 
genes, and protect hepatocytes from inflammatory diseases associated with oxidative 
stress18,19. We investigated if DARTs could deliver Nrf2 to HepG2 cells and upregulate the 
transcription of anti-oxidant genes that are regulated by Nrf2, in particular, Heme 
oxygenase-1 (HO-1), NAD(P)H dehydrogenase (quinone) (NQO1), and Glutamate-cysteine 
ligase catalytic subunit (GCLC) 4,20. We selected these three genes for analysis because of 
their central role in protecting against oxidative stress, and because they are signatures of 
Nrf2 activity. For example, HO-1 increases carbon monoxide production and is therapeutic 
against a wide variety of inflammatory diseases21. In addition, NQO1 up-regulates quinone 
anti-oxidant production and GCLC increases the production of glutathione, both of which 
protect against oxidative stress by remodeling metabolic and cell signaling pathways 4,22.
Nrf2 was bound to DARTs at a 1:1 molar ratio (DART-Nrf2) and was incubated with 
HepG2 cells at a 0.6 μM concentration overnight and then analyzed for gene expression via 
reverse transcription PCR (RT-PCR). As a control, HepG2 cells were treated with free Nrf2. 
Figure 4a demonstrates that DARTs can deliver functional Nrf2 into hepatocytes and induce 
the expression of Nrf2 target genes. For example, HepG2 cells treated with DART-Nrf2 had 
a significant increase in HO-1 expression in comparison to cells treated with Nrf2 or control 
cells. Similarly, DART-Nrf2 was able to increase the transcription of NQO1 and GCLC, 
whereas free Nrf2 had no effect on these genes.
We also investigated if the transcription of Nrf2 downstream genes by DART delivered Nrf2 
could protect hepatocytes from oxidative stress. HepG2 cells were pretreated with a 200 μM 
concentration of hydrogen peroxide for 4 hours, to induce oxidative stress, and then treated 
with either free Nrf2 or DART-Nrf2 (0.6 μM) for 14 hours. Cellular oxidative stress was 
measured with CM-H2DCFDA using flow cytometry (see Supplementary Information S9.3 
for details). Figure 4b demonstrates that DART delivered Nrf2 can protect hepatocytes from 
hydrogen peroxide induced oxidative stress. Cells treated with hydrogen peroxide had a 2.5 
fold increase in CM-H2DCFDA oxidation, whereas this was reduced down to levels 
comparable to the control with DART-Nrf2. In contrast, Nrf2 by itself had a minimal effect 
on cellular oxidative stress levels. Thus, DARTs are able to deliver functional Nrf2, induce 
the transcription of antioxidant genes, and protect cells against oxidative stress.
Nrf2 delivered by DARTs has great potential for treating liver associated inflammatory 
diseases, such as acute liver failure and liver fibrosis, which collectively effect millions of 
people each year4,10,11. We investigated if Nrf2 delivered by DARTs could protect mice 
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against acetaminophen (APAP) induced liver injury. APAP induced liver injury was 
selected as an initial disease model for the DARTs because of the great need for new 
therapeutics against this disease23,24 and the well-established role of Nrf2 in protecting 
against APAP induced liver injury. APAP induced toxicity in mice was induced via the i.p. 
injection of APAP (500mg/kg), and 1 hour afterwards an intravenous injection of either free 
Nrf2 or DART-Nrf2 was given. Liver toxicity was determined 24 hours later by measuring 
ALT levels in the serum and also via histology. Additionally, liver tissue was isolated from 
these mice and analyzed by western blotting to determine if Nrf2 delivered by the DARTs 
could induce the expression of Nrf2 downstream genes (see Supplementary Information S11 
for details).
Figures 5a–c demonstrate that DARTs can enhance the delivery of Nrf2 in vivo, induce the 
transcription of Nrf2 downstream genes, and protect mice from APAP induced liver injury. 
For example, Figure 5a demonstrates that mice receiving DART-Nrf2 and APAP had a four-
fold decrease in ALT levels in comparison to mice that received APAP only, or mice that 
received APAP and free Nrf2. A similar therapeutic benefit was observed in the histology 
sections of the mice that received DART-Nrf2 and APAP, which had a histological profile 
similar to healthy mice, in contrast mice receiving free Nrf2 and APAP had significant signs 
of toxicity (Fig. 5b). Importantly, DART-Nrf2 was able to have a therapeutic effect on 
APAP treated mice, even though it was given an hour after APAP administration, suggesting 
that it can be effective in a clinical scenario where patients present hours after drug intake. 
In addition, we investigated if Nrf2 complexed with DARTs could stimulate the 
transcription of Nrf2 downstream genes in vivo, via western blotting for the Nrf2 
downstream genes HO1 and NQO1. Figure 5c demonstrates that Nrf2 delivered by the 
DARTs can increase the expression of HO1 and NQO1 in the liver, and suggests that the 
therapeutic effects of DART delivered Nrf2 are due to the enhanced transcription of Nrf2 
downstream genes.
We performed additional experiments to determine if the endosomal disruptive or galactose 
targeting groups of the DARTs were essential for Nrf2 delivery in vivo. To determine the 
importance of the endosomal disruptive unit, we synthesized galactose conjugated DNA and 
investigated its ability to deliver Nrf2 and rescue mice from APAP induced liver injury. 
Figure 5a demonstrates that galactose conjugated DNA is unable to deliver Nrf2 in vivo, 
demonstrating that the endosomal disruptive unit of the DARTs is critical for efficacy. In 
addition, we performed experiments to determine if the galactose targeting groups of the 
DARTs were critical for Nrf2 delivery. DARTs containing glucose residues instead of 
galactose were synthesized and their ability to rescue mice from APAP induced liver injury 
was investigated. Figure 5a demonstrates that glucose containing DARTs were inefficient at 
delivering Nrf2, but were more effective at delivering Nrf2 than galactose conjugated DNA. 
Thus the galactose targeting plays a role in enhancing Nrf2 delivery in vivo, but is perhaps 
not as important as the endosomal disruption unit.
In this report we present a multifunctional oligonucleotide, termed DARTs, which can 
deliver transcription factors in vivo. The DART delivery strategy has numerous potential 
applications given the central role of transcription factors in liver biology. In addition, it 
should be possible to deliver transcription factors to cell types outside of the liver by using 
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targeting groups other than galactose. Finally, the DART delivery strategy demonstrates that 
DNA based scaffolds can be used to deliver DNA binding proteins and provides a platform 
for the development of DNA origami-based delivery vehicles.
Materials and Methods
Synthesis of the DARTs
The synthesis of the DARTs is shown in detail in the supporting information and is 
described in Figures S1 and S2.
In vitro delivery of Nrf2 with DARTs
HepG2 cells were cultured in DMEM media containing 10% FBS and antibiotics (Pen 
Strep). Cells with a passage number less than 15 were used for experiments. HepG2 and 
Hepa-1C1C7 cells were seeded at 40% confluency the day before experiments. Nrf2 and 
DARTs were mixed at equal molar ratios and incubated for 15 min in binding buffer before 
the addition to cells. For all in vitro studies, 0.6 μM of Nrf2 or 0.6 μM of Nrf2 complexed 
with 0.6 μM of DARTs were used.
Reverse transcription PCR (RT-PCR) analysis of HepG2 cells treated with Nrf2 delivered by 
DARTs
HepG2 cells were treated with either free Nrf2 or DART-Nrf2 in culture media for 24 h and 
the RNA was extracted from the cells using the RNeasy® Mini Kit with additional DNase I 
digestion (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. RNA purity 
and concentration were determined by measuring the optical density using an ND-1000 
Spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). Purified 
mRNAs were normalized by total mRNA concentration, and Qiagen one-step RT-PCR was 
conducted with primers for HO1, NQO1, GCLC, and GAPDH, which were purchased from 
Origene. Amplified DNAs were visualized with a ChemiDoc XRS system, after gel 
electrophoresis in a 1% agarose gel and staining with SYBR safe.
Intracellular localization of Nrf2 delivered by DARTs
The intracellular localization of Nrf2 delivered by the DARTs was observed by confocal 
microscopy (Swept Field Confocal microscope-Prairie Technology). Nrf2 was labeled with 
Alexa555 to visualize its intracellular localization. 500 μg of Nrf2 (500 μg/mL) was reacted 
with 9 times molar excess of Alexa555-NHS-ester (Life Technologies) at 4°C overnight in 
0.1 M phosphate buffer (pH 8.5). A PD-10 column was used to remove unreacted Alexa555. 
The concentration of Nrf2 and conjugated Alexa555 were measured with Nanodrop 2000 
(Thermo). Alexa555-Nrf2 and DART were mixed at equal molar ratios and incubated for 15 
min. HepG2 cells in 35 cm culture dishes were treated with 0.6 μM of Alexa555-Nrf2 
prepared with or without DARTs for 30 min. After PBS wash, cells were incubated for 
additional 4 hr in culture medium. 100nM of Lysotracker Green DND-26 (Life 
Technologies) was added to the cells to visualize endosomes and lysosomes. HepG2 cells 
were washed with PBS and images were taken using confocal microscopy.
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Intracellular uptake analysis of Cy3-DART in HepG2 cells
3′-azide functionalized oligonucleotides containing the Nrf2 consensus sequence and Cy3, 
(forward strand 5′-/Cy3/GTC ACA GTG ACT CAG CAG AAT CTG TTT T-N3-3′) and 
(reverse strand 5′-CAG ATT CTG CTG AGT CAC TGT GAC TTT TT-N3-3′) were 
purchased from IDT. Cy3 labeled DARTs were synthesized following procedures described 
in the Supplementary Information (see Supplementary Information S2.2 for details). HepG2 
cells were treated with 0.6 μM of either Cy3-DNA or Cy3-DARTs in OptiMEM medium 
with 1% FBS for 24hr. HepG2 cells were washed 3 times with PBS and analyzed with flow 
cytometry (Guava easyCyte™).
Treatment of acetaminophen (APAP) induced liver injury in mice with DART-Nrf2
After overnight fasting, mice were administered an intraperitoneal injection of APAP (500 
mg/kg) dissolved in PBS (5% DMSO). One group of mice received free Nrf2 at the dose of 
25 μg per mouse (1.25 mg/kg of Nrf2), and the other groups of mice were administered 
DARTs, DART-Nrf2, glucose-DART-Nrf2, and Gal-DNA-Nrf2 in 100 μL of PBS by tail-
vein injection. 24 h after the injection of APAP, the mice were euthanized by CO2 
asphyxiation. The blood was collected by cardiac puncture and the livers were isolated. 
APAP-induced liver injury was determined by measuring the alanine aminotransferase 
(ALT) activity in the serum using a commercial ALT assay kit (Biovision). Liver samples 
were used for RNA isolation and histology to assess the liver damage. For histological 
analysis livers sections were stained by Hematoxylin and eosin, observed under light 
microscopy (Zeiss AxioCam ERc 5s), and the necrosis was compared between the groups of 
control, Nrf2 and DART-Nrf2 treated mice. Western blotting was performed with the liver 
samples to analyze the expression of HO1, NQO1, and GAPDH, using standard procedures. 
Transfer of proteins from liver homogenates to the nitrocellulose membrane (Bio-rad) was 
performed at 65V for 60 min. Primary antibodies (1:500) were incubated overnight at 4C 
and the secondary antibody, bovine anti-rabbit-HRP, (1:2000) was incubated for 2 hr at RT. 
Images were taken using a ChemiDoc XRS system (Bio-Rad Laboratories). HO1 antibody 
(sc-10789), NQO1 antibody (sc-25591), and bovine anti-rabbit IgG-HRP (sc-2370) were 
purchased from Santa Cruz Biotech.
Detailed experimental procedures regarding the DART synthesis, characterization, and in 
vitro and in vivo testing are described in the Supplementary Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DARTs are multifunctional oligonucleotides that can deliver the transcription factor 
Nrf2 in vivo
DARTs are composed of an oligonucleotide that contains an Nrf2 promoter sequence and 
hydrophobic membrane disruptive domains that are masked by acid cleavable galactose 
residues. DARTs complex Nrf2 and deliver Nrf2 to the liver via galactose mediated 
endocytosis. After endocytosis, DARTs stimulate endosomal disruption and the release of 
Nrf2 into the cytoplasm, due to acid catalyzed unmasking of their hydrophobic domains.
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Figure 2. The DARTs are acid sensitive endosomal disruptive agents and their hydrolysis is pH 
sensitive
a, The hydrolysis of the DARTs is acid catalyzed. DART hydrolysis was conducted at pH 5 
and pH 7.4 PBS, ± S.E, n=5.
b, DARTs disrupt calcein containing liposomes in a pH-dependent manner. Liposome 
disruption by the DARTs was assessed by calcein leakage, mean ± S.E, n=5. **, p < 0.01.
c, Nrf2 binds the DARTs in 10% serum. An electrophoretic mobility shift assay on Nrf2-
DART complexes demonstrates that the migration of the DARTs is shifted after 
complexation with Nrf2 in serum.
d, DARTs alter the intracellular delivery of Nrf2 and enhance lysosomal release. Alexa555 
labeled Nrf2 (red color) was complexed with the DARTs and incubated with HepG2 cells. 
Endosomes were counterstained with Lysotracker green (green color). Nrf2 complexed with 
the DARTs have a substantially different intracellular distribution than free Nrf2, with a 
Lee et al. Page 11
Nat Mater. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
large fraction existing outside of the lysosome, whereas free Nrf2 is predominantly on the 
cell membrane or in lysosomes. (Scale bar: 5 μm).
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Figure 3. The DARTs can target hepatocytes and enhance the delivery of Nrf2 to the liver
a, Hepa-1C1C7 cells were treated with Cy3-DNA or Cy3-DART for 4 hours and uptake was 
measured via flow cytometry. Cy3 labeled DARTs have enhanced uptake in Hepa-1C1C7 
cells and have 8 times higher mean red fluorescence than free DNA.
b, DARTs enhance the liver delivery of Nrf2. Nrf2 labeled with IRDye 800CW-NHS-ester 
was complexed with the DARTs, and injected into mice. The biodistribution of Nrf2 was 
quantified via fluorescence 4 hours after Nrf2 injection. DARTs enhance the liver delivery 
of Nrf2 by a factor of 1.4. mean ± S.E, n=6. *, p < 0.05.
Lee et al. Page 13
Nat Mater. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. DARTs are able to deliver Nrf2 to hepatocytes, up-regulate Nrf2 downstream genes, 
and can protect hepatocytes against reactive oxygen species (ROS)
a, Nrf2 delivered by DARTs enhances the expression of HO1, NQO1, and GCLC. RT-PCR 
of HepG2 cells treated with DART-Nrf2 complexes up-regulate HO1, NQO1, and GCLC. 
Free Nrf2 had no effect on HO1, NQO1, and GCLC gene expression.
b, Nrf2 delivered by DARTs reduces ROS levels in HepG2 cells stressed with hydrogen 
peroxide. ROS levels in hydrogen peroxide stressed cells were not significantly reduced by 
free Nrf2, whereas DART-Nrf2 decreased ROS production down to levels comparable to 
control cells, mean ± S.E, n=9. **, p < 0.01, ns = statistically not significant.
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Figure 5. The DARTs can deliver Nrf2 to the liver, up-regulate Nrf2 downstream genes, and 
rescue mice from acetaminophen induced liver injury
a, Nrf2 delivered by DARTs rescue mice from acetaminophen (APAP) induced liver injury. 
DART-Nrf2 complexes reduce serum alanine transaminase (ALT) levels in APAP treated 
mice by a factor of 4. Free Nrf2 had no effect. Nrf2 complexed with either Glu-DARTs or 
Gal-DNA, and free DARTs, did not cause a statistically significant reduction in ALT levels. 
mean ± S.E, n=10. p < 0.01, ns = statistically not significant to APAP.
b, Nrf2 delivered by DARTs reduces liver damage in APAP treated mice. Histological 
sections of livers from APAP treated mice had significant inflammation. In contrast, 
histological sections of livers from APAP mice treated with DART-Nrf2 had reduced liver 
damage and resembled the histological sections of healthy mice. Free Nrf2 was unable to 
suppress liver damage. (Scale bar: 40 μm).
c, Nrf2 delivered by DARTs enhances the expression of the proteins HO1 and NQO1 in the 
liver. APAP treated mice were given either DART-Nrf2 or free Nrf2, and their livers were 
harvested and western blot analysis was conducted for the proteins HO1, NQO1, and 
GAPDH. Mice treated with DART-Nrf2 complexes have increased HO1 and NQO1 
expression in comparison to free Nrf2 or APAP treated mice. Control = no treatment, APAP 
= APAP only, Nrf2 = APAP+Nrf2, DART = APAP+DART-Nrf2.
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